[Degranulation of human eosinophilic granulocytes by the platelet activating factor].
Incubation of purified human eosinophil granulocytes (greater than 93%) with the platelet activating factor (PAF), led at concentrations of 1 pM to 10 microM, to a non-cytotoxic and dose-dependent liberation of proteins both from the "small" and the "specific" granules. The mean EC50 for this PAF-induced effect was 1.47 nM (n = 9), with a maximum at 100 nM PAF. The degranulating effect of PAF can be inhibited competitively by the specific PAF-receptor antagonist, WEB 2086 (KB between 12 and 13 nM), and is Ca2(+)-dependent.
Kroegel
C
C
Department of Thoracic Medicine, Brompton Hospital, University of London, United Kingdom.
Venge
P
P
Matthys
H
H
Barnes
P J
PJ
D015550:Cell Degranulation / Q000187:drug effects*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004802:Eosinophilia / Q000276:immunology; D004804:Eosinophils / Q000187:drug effects*; D006801:Humans; D010972:Platelet Activating Factor / Q000494:pharmacology*
D010972:Platelet Activating Factor
Degranulation humaner eosinophiler Granulozyten durch den Platelet Activating Factor (PAF).